Analyst Ratings For VBI Vaccines (NASDAQ:VBIV)
Today, Noble Financial reiterated its Buy rating on VBI Vaccines (NASDAQ:VBIV).
There are 2 buy ratings on the stock.
The current consensus rating on VBI Vaccines (NASDAQ:VBIV) is Buy (Score: 3.00) with a consensus target price of $6.00 per share, a potential 29.31% upside.
Some recent analyst ratings include
- 7/31/2017-Noble Financial Reiterated Rating of Buy.
- 10/10/2016-Laidlaw initiated coverage with a Buy rating.
- 7/26/2016-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
Recent Insider Trading Activity For VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines (NASDAQ:VBIV) has insider ownership of 34.10% and institutional ownership of 29.20%.
- On 12/6/2016 Perceptive Advisors Llc, Major Shareholder, bought 3,383,955 with an average share price of $3.05 per share and the total transaction amounting to $10,321,062.75. View SEC Filing
- On 8/14/2015 Perceptive Advisors Llc, Major Shareholder, bought 650,000 with an average share price of $2.08 per share and the total transaction amounting to $1,352,000.00. View SEC Filing
- On 9/30/2013 Murray George Smith, CFO, bought 3,027 with an average share price of $1.13 per share and the total transaction amounting to $3,420.51. View SEC Filing
- On 8/21/2013 Murray George Smith, CFO, bought 8,973 with an average share price of $1.17 per share and the total transaction amounting to $10,498.41. View SEC Filing
Recent Trading Activity for VBI Vaccines (NASDAQ:VBIV)
Shares of VBI Vaccines closed the previous trading session at 4.64 down -0.09 -1.90% with 130,126 shares trading hands.
